A Faster CBD Peak Did Not Mean Greater Total Exposure in a Formulation Trial
Two enhanced CBD formulations changed absorption differently in a small crossover trial. The liquid reached its peak sooner, while the enhanced capsule produced greater overall exposure. Neither result demonstrated better treatment of a disease.
An equal-dose comparison
Twelve healthy men entered the study; nine completed all three treatment periods. Each formulation supplied 40 mg CBD: an enhanced capsule, an enhanced liquid or a reference capsule containing unformulated CBD isolate and filler. Doses followed a standardized low-fat breakfast.
Researchers measured plasma CBD and 7-hydroxy-CBD over 72 hours. This was an open-label pharmacokinetic experiment, not a blinded efficacy trial in patients seeking relief from pain, anxiety or seizures.
Rate and extent of exposure separated
The enhanced liquid had the earliest reported median time to peak. The enhanced capsule had the highest mean peak CBD concentration and largest reported exposure over the sampling interval. The reference capsule had lower exposure than either enhanced formulation.
A product can deliver CBD sooner without producing the greatest total exposure. Peak concentration, time to peak and area under the concentration-time curve describe different features. Combining them into one claim of being better obscures the comparison.
The reference product matters
The reference was an unformulated isolate capsule, not every oil, prescription solution or retail CBD product. Superiority over products that were not tested cannot be inferred.
Greater relative exposure is also not absolute bioavailability. Without an appropriate intravenous comparison, the experiment cannot directly determine the fraction of the administered dose reaching systemic circulation.
Clinical benefit remains a separate question
The small all-male sample and single-dose design limit generalization. The sponsor supplied products and funding, and two authors held company roles. Independent replication would be valuable.
The appropriate conclusion is a formulation-specific difference in plasma exposure. Choosing treatment, substituting products or predicting symptom improvement requires evidence beyond this pharmacokinetic comparison.
For the separate forensic question, see our discussion of cannabinoid concentrations and evidence of impairment.
Primary research
Randomized single-dose crossover comparative bioavailability study of two novel oral cannabidiol (CBD) formulations in healthy volunteers under fed conditions, compared to a standard CBD isolate capsule. Journal of Cannabis Research (2025). DOI: 10.1186/s42238-025-00312-9.
